Monday, July 22, 2024
HomeFunding CA-based BioAge Labs Secures $170Million in Series D Round Funding

[Funding alert] CA-based BioAge Labs Secures $170Million in Series D Round Funding

CA-based BioAge Labs secures $170million in series D round funding. The round was led by Sofinnova Investments.

CA-based BioAge Labs secures $170million in series D round funding. The round was led by Sofinnova Investments.

In addition to Andreessen Horowitz (a16z) Bio + Health, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, and Amgen Ventures invested.

Read also – NYC-based Tandym Group Acquired Kolter Solutions

In connection with the funding, Sofinnova Investments managing partner James Healy, M.D., Ph.D., will join BioAge as Chairman of the Board, and Longitude Capital managing director Patrick Enright will join as Board Director.

The funds will progress Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline. BioAge, led by CEO Kristen Fortney, is a clinical-stage biotechnology business developing metabolic disease targets and therapeutics using human aging biology.

Read also – FL-based Odyssey Secures $6Million in Funding

Azelaprag, the company’s flagship program, is a potential first-in-class oral APJ agonist in Phase 2 trials with tirzepatide to treat obesity in older adults. Oral azelaprag may boost weight loss and body composition in incretin-treated obese patients. Unique insights from its research platform based on human longevity data inform its preclinical programs on metabolic aging pathways.

Kristen Fortney said “This funding will support us through key clinical milestones and data readouts for our lead compound azelaprag in obesity, as well as advance our earlier-stage metabolic aging pipeline. The azelaprag program highlights our discovery platform’s ability to identify novel approaches to treating metabolic disease.”

About BioAge

BioAge, a clinical-stage biotechnology startup, uses human aging biology to identify metabolic disease targets and treatments. Their patented platform, which includes >65M molecular data from 45+ years of human aging, unlocks new biological insights and druggable mechanisms for age-related disease.

Read also – IL-based Ascent Technologies Acquired Waymark

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular